The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 84)
Research Grant, 2017
Parkinson's disease (PD) is characterized by impairment of motor control as a result from extensive neuron death. The primary mechanism responsible for the progressive neuronal loss in PD remains unknown; however, clues have been obtained from families who have a genetic form of PD that is accompanied by a mutation (change in genetic material, or DNA) in an important protein called...
Researchers: Claudio Hetz Flores, PhD
Target Validation, 2015
Lysosomes are key intra-cellular organelles involved in the degradation of proteins including alpha-synuclein. Lysosomal protein degradation systems fail in Parkinson's disease (PD). Nedd4 and glucocerebrosidase (GBA) are two important targets involved in the clearance of alpha-synuclein through lysosomal pathways. We have previously shown that overexpression of ...
Researchers: Penelope Hallett, PhD
Priority Target Award, 2015
Study of the Molecular and Cellular Consequences of LRRK2 Kinase Inhibition in Neurons and Microglia
Mutations in leucine-rich repeat kinase-2 (LRRK2) are the greatest known genetic cause of Parkinson's disease (PD). LRRK2 inhibitors may represent a new type of disease-modifying therapies, as several lines of evidence support the beneficial effects of this class of drugs. In this study, we will investigate the molecular and cellular effects of LRRK2 kinase inhibition in neurons a...
Rapid Response Innovation Awards, 2014
BPOZ-2 is an anti-tumor protein that has been reported to stimulate the removal of cancer- related protein aggregates in cancer cells. However, its role has never been explored in Parkinson's disease (PD) and other neuronal disorders. In PD, a group of neurons located in the midbrain is damaged due to the accumulation of alpha-synuclein proteins. Therefore, we want...
Researchers: Avik Roy, PhD
Target Validation, 2014
Poor handling and elimination of misfolded proteins has been identified as central in the development of Parkinson's disease (PD). A special class of proteins within the cell called "chaperones" can assist in improving protein handling. Our project will target a chaperone inhibitor called BAG5 that we know compromises protein handling and the function of other proteins importan...
Researchers: Suneil K. Kalia, MD, PhD, FAANS, FRCS